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Improving Life Expectancy of HIV 
Patients
Increase in CV related mortality
Hanna et al., Clinical Infectious 
Diseases. 2016; 63(8), 1122-1129.
Comorbidities in the 
U.S. HIV population
Gallant et al., The Journal of Infectious Diseases. 2017; 216(12), 1525-1533
HIV and Relative Risk of ASCVD
•50-100% higher risk of major adverse 
cardiovascular events (MACE)
•Cardiovascular death
•Non-fatal myocardial infarction
•Non-fatal stroke
•Need for major revascularization
Islam et al., HIV Medicine. 2012; 13(8): 453-68
Traditional Risk Factors for ASCVD
•Smoking
•Age
•Hypertension
•Dyslipidemia
•Family history of premature ASCVD
•Diabetes
Effect of smoking prevalence in 
developing ASCVD in HIV patients
Smoking (frequency and impact) accounts for  ~25% of higher 
attributable risk of MACE in patients living with HIV
General Population HIV Population
% of US adults who are 
current smokers
21% 46-76%
Increased risk in 
developing ASCVD
3 fold 4-5 fold
Lifson et al., American Journal of Public Health. 2010; 100(10), 1896-1903.
Vascular Inflammation and ASCVD
• Vascular inflammation increases ASCVD and event risk
• HIV causes chronic inflammation
• Inflammatory biomarkers: C-reactive protein, IL-6, TNF 
receptor II, endothelial activation marker
Participants with CVD event Participants without CVD 
event
C-Reactive Protein (hsCRP) 
(µg/mL)
3.34 1.67
Interleuken-6 (IL-6) (pg/mL) 3.07 1.72
D-Dimer (µg/mL) 0.31 0.20 Duprez et al., PLoS
ONE. 2012; 7(9)
Cardiovirology Clinic
• A senior ETSU Heart faculty cardiologist established a 
Cardiovirology clinic at the ETSU Center of Excellence for 
HIV/AIDS care in September 2017 to provide:
• Primary prevention of major CV events in HIV population
• Secondary prevention and disease management in HIV 
patients with established CVD
• Aggressive intervention consistent with AHA/ACC 
guidelines and recent research
• Coordination with PCP and HIV practitioners, pharmacists 
and other members of interdisciplinary team
Patient Identification
General 
Cardiology 
Providers
Infectious 
Disease 
Providers 68 
Cardiovirology
patients 
identified
Initial 
Consultation
Follow-up visit
10 patients with 
established CVD 
excluded
Methods -1
D:A:D 5-year risk score (reduced model) calculated at 
initial consult and most recent visits. Data elements include:
• Age
• Sex
• Present or past smoking history
• History of premature ASCVD in first degree relatives
• (<55 yo male, <65 yo female)
• Diabetes
• CD4 cell count
• Systolic BP
• Total Cholesterol
• HDL Cholesterol
Retrieved from: https://chip.dk/Tools-Standards/Clinical-risk-scores

Methods -2
•Additional Data collected: 
• Personal History of ASCVD
• Body-mass index and systolic (SBP) and diastolic (DBP) 
blood pressures
• Laboratory Values
• CD4 count 
• HIV-1 viral load
• Proteinuria
• Estimated glomerular filtration rate
• Triglycerides (TG)
• Low Density Lipoprotein cholesterol (LDL)
Analysis
•Univariate analysis 
•Two-tailed, paired T-testing to identify 
significant differences in mean parameter 
values (initial vs. most recent visits)
•Significance: p <0.05
Primary Findings
p<0.0001
Mean Values±SD
p<0.00000001 p<0.0000001
p<0.002
p<0.002
Secondary 
Findings:
Lipids
p<0.0003 p<0.0004
Secondary Findings: Blood Pressure
Conclusion
• Patients living with HIV who received primary preventive 
cardiovascular care in the ETSU Cardiovirology Clinic 
enjoyed meaningful reductions in their D:A:D 5-yr MACE 
risk score 
• Significant reductions seen in: TG, TC, LDL, SBP, DBP
• Blood pressure and lipid interventions likely influenced risk 
reduction
• Aggressive control may be most important in these well-controlled 
HIV patients
• Findings suggest the potential efficacy of the Cardiovirology
Clinic model
Limitations
•Too few data points due to:
• Short duration of follow up (<1 year)
• Small patient population (n=58)
•D:A:D risk score surrogate for clinical outcomes
• All CV risk estimation equations have inherent 
inaccuracies
•Other risk factor modifications may have been 
identified as effective with larger patient population 
and longer follow-up.
